MedTrace Logo

Effect of Exenatide on Cortisol Secretion

NCT03160261 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-05-03

No results posted yet for this study

Summary

The primary aim of the study is to describe the effect of single dose of 10 micrograms (μg) exenatide given subcutaneously (s/c) on cortisol secretion. Secondary outcomes involve ACTH and glucose levels.

Conditions

  • Healthy

Interventions

DRUG

Exenatide Injection

Single injection of Exenatide 10μg subcutaneously

Sponsors & Collaborators

  • University of Tartu

    lead OTHER

Principal Investigators

  • Vallo Volke, MD,PhD · University of Tartu

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-07
Primary Completion
2017-12-28
Completion
2017-12-28

Countries

  • Estonia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03160261 on ClinicalTrials.gov